Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Sucampo Pharma Inc (SCMP)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 757,900
  • Shares Outstanding, K 46,640
  • Annual Sales, $ 230,060 K
  • Annual Income, $ 18,490 K
  • 36-Month Beta 1.47
  • Price/Sales 3.24
  • Price/Cash Flow 6.64
  • Price/Book 18.83

Price Performance

See More
Period Period Low Period High Performance
1-Month
10.10 +60.64%
on 11/16/17
17.70 -8.33%
on 12/07/17
+5.53 (+51.64%)
since 11/10/17
3-Month
9.45 +71.69%
on 11/02/17
17.70 -8.33%
on 12/07/17
+3.48 (+27.25%)
since 09/12/17
52-Week
9.30 +74.46%
on 04/18/17
17.70 -8.33%
on 12/07/17
+0.98 (+6.39%)
since 12/12/16

Most Recent Stories

More News
Incyte (INCY) Reports Phase III Follow-Up Data for Jakafi

Incyte (INCY) announced new 208-week (4-year) follow-up data from the phase III RESPONSE study of Jakafi.

SCMP : 16.35 (+0.62%)
JNJ : 143.02 (+1.33%)
INCY : 96.24 (-1.04%)
NVS : 84.05 (+0.30%)
3 Drug/Biotech Stocks Up More Than 10% This Week

The drugs/biotech sector is down this week due to broader market pressure, except a few stocks.

SCMP : 16.35 (+0.62%)
AGN : 172.66 (-0.06%)
VTGN : 1.15 (-5.74%)
RVNC : 35.40 (-1.53%)
Roche Reports Tecentriq/Avastin Lung Cancer Study Data

Roche (RHHBY) announced interim results from the phase III IMpower150 study of Tecentriq and Avastin plus chemotherapy in people with advanced form of lung cancer.

CORT : 17.32 (+1.70%)
SCMP : 16.35 (+0.62%)
JNJ : 143.02 (+1.33%)
RHHBY : 30.3050 (+0.15%)
Sucampo Pharmaceuticals (SCMP) in Focus: Stock Moves 5.6% Higher

Sucampo Pharmaceuticals(SCMP) was a big mover last session, as the company saw its shares rise nearly 6% on the day.

ALDX : 6.67 (-1.91%)
SCMP : 16.35 (+0.62%)
Bristol-Myers' Opdivo's Lung Cancer Study Meets Early Success

Bristol-Myers' (BMY) phase III study evaluating Opdivo versus docetaxel was stopped earlier than expected as it met the primary endpoint.

CORT : 17.32 (+1.70%)
SCMP : 16.35 (+0.62%)
MRK : 56.85 (+0.91%)
BMY : 63.47 (+0.71%)
Glaxo Submits NDA for Anti Relapse Malaria Medicine to FDA

Glaxo (GSK) and partner Medicines for Malaria Venture filed a new drug application (NDA) with the FDA for single-dose anti relapse medicine for malaria.

CORT : 17.32 (+1.70%)
LGND : 136.36 (+0.96%)
SCMP : 16.35 (+0.62%)
GSK : 35.52 (+0.59%)
AstraZeneca's Tagrisso Label Expansion Filing Accepted by EMA

AstraZeneca's (AZN) Marketing Authorisation Application for label expansion of Tagrisso has been accepted by the European Medicines Agency.

CORT : 17.32 (+1.70%)
LGND : 136.36 (+0.96%)
AZN : 33.35 (+0.69%)
SCMP : 16.35 (+0.62%)
Catalyst (CPRX) Reports Positive Phase III Data on Firdapse

Catalyst (CPRX) reported encouraging top-line results from a phase III study for its pipeline candidate, Firdapse, for the treatment of Lambert-Eaton myasthenic syndrome.

LGND : 136.36 (+0.96%)
SCMP : 16.35 (+0.62%)
BMRN : 89.11 (+1.13%)
CPRX : 4.22 (+0.48%)
New Strong Buy Stocks for November 28th

New Strong Buy Stocks for November 28th

MEI : 41.05 (+0.49%)
SCMP : 16.35 (+0.62%)
EBS : 44.86 (+1.68%)
PKX : 76.13 (-0.89%)
BAK : 26.48 (-0.97%)
Free Research Reports on These Healthcare Stocks -- Sanofi, DURECT, Sucampo Pharma, and Perrigo

In keeping with the commitment to dynamically provide members with timely information WallStEquities.com has issued free tailored Stock Review on SNY, DRRX, SCMP, and PRGO which is a click away at http://www.wallstequities.com/registration....

DRRX : 1.01 (unch)
SCMP : 16.35 (+0.62%)
SCHW : 51.52 (+1.58%)
SNY : 43.86 (+0.37%)
PRGO : 86.62 (+1.20%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Buy with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Maximum. Long term indicators mostly agree with the trend.

See More

Business Summary

Sucampo Pharmaceuticals, Inc. is focused on the development and commercialization of specialized medicines that meet major unmet medical needs of patients worldwide. Sucampo has two marketed products - AMITIZA, its lead product, and RESCULA - and a late-stage pipeline of product candidates in clinical...

See More

Key Turning Points

2nd Resistance Point 16.95
1st Resistance Point 16.60
Last Price 16.35
1st Support Level 15.60
2nd Support Level 14.95

See More

52-Week High 17.70
Last Price 16.35
Fibonacci 61.8% 14.49
Fibonacci 50% 13.50
Fibonacci 38.2% 12.51
52-Week Low 9.30

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.